Last reviewed · How we verify

Laida Cuevas Palomares — Portfolio Competitive Intelligence Brief

Laida Cuevas Palomares pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
RiTUXimab Injection [Truxima] RiTUXimab Injection [Truxima] marketed Monoclonal antibody (anti-CD20) CD20 Oncology, Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Amgen · 1 shared drug class
  2. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  3. Beijing Friendship Hospital · 1 shared drug class
  4. Centre Hospitalier Universitaire de Saint Etienne · 1 shared drug class
  5. Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH · 1 shared drug class
  6. Dr. Reddy's Laboratories Limited · 1 shared drug class
  7. Gruppo Italiano Terapie Innovative nei Linfomi · 1 shared drug class
  8. Hoffmann-La Roche · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Laida Cuevas Palomares:

Cite this brief

Drug Landscape (2026). Laida Cuevas Palomares — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/laida-cuevas-palomares. Accessed 2026-05-16.

Related